Opinion|Videos|April 4, 2025
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
Panelists discuss how medical professionals select PSMA PET tracers based on factors such as diagnostic accuracy, tracer availability, patient-specific considerations, and logistical aspects such as half-life and production facilities. Fluorine-18 (^18F)–labeled tracers, such as ^18F-PSMA-1007, offer logistical advantages due to their longer half-life and higher image resolution, facilitating broader clinical application.
Advertisement
Video content above is prompted by the following:
- What factors do you consider when selecting a PSMA PET tracer for a particular patient or clinical scenario?
- When might you opt for F18 vs Ga58, and how do available data inform your decision?
- Meta-analysis F18 vs G68 (Huang et al. Prostate Cancer. 2023)
- Do you still see a role for Axumin? If so, in what scenarios?
Advertisement
Related to this article
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5